التداول ينطوي على مخاطر
الاستثمارات تنطوي على مخاطر وليست مناسبة لجميع المستثمرين. العقود مقابل الفروقات هي أدوات معقدة وتنطوي على مخاطر عالية لخسارة الأموال بسرعة بسبب الرافعة المالية.
التداول ينطوي على مخاطر
الاستثمارات تنطوي على مخاطر وليست مناسبة لجميع المستثمرين. العقود مقابل الفروقات هي أدوات معقدة وتنطوي على مخاطر عالية لخسارة الأموال بسرعة بسبب الرافعة المالية.
Novo Nordisk A-S
Closed
Sector Healthcare
101.73 -3.45
Overview
Share price change
24h
Min
101.58
Max
101.95
Income | -5.4B 20B |
|---|---|
Sales | 2.7B 68B |
P/E Sector Avg | 49.94 104.138 |
EPS | 4.49 |
Profit margin | 29.459 |
EBITDA | -1.2B 36B |
Recommendations | Buy |
|---|---|
12 Months Forecast | +51.61 upside |
Market Cap | 4.1B 380B |
|---|---|
Previous open | 105.18 |
Previous close | 101.73 |
News Sentiment
By Acuity
36%
64%
125 / 392 Ranking in Healthcare
Technical Score
By Trading Central
Confidence
Weak Bullish Evidence
Novo Nordisk A-S Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Novo Nordisk A-S Forecast
Price Target
By TipRanks
51.61% upside
12 Months Forecast
Average 154.25 USD 51.61%
High 160 USD
Low 146 USD
Based on 6 Wall Street analysts offering 12 month price targets forNovo Nordisk A-S - Dist in the last 3 months.
Sentiment
By Acuity
125 / 392 Ranking in Healthcare
News Sentiment
Bullish Evidence
Volatility
Below average
News Volume (RCV)
Above average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
EBITDA
Operating profit
$
About Novo Nordisk A-S
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
